Top Markets
#1 Verus Coin Verus Coin +45.28%
#2 Status Status +19.17%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.58%
#4 GoPlus Security GoPlus Security +16.92%
#5 Wrapped NXM Wrapped NXM +15.51%
#6 Ontology Gas Ontology Gas +11.14%
#7 DMT-NAT DMT-NAT +9.14%
#8 BankrCoin BankrCoin +8.23%
#9 Pons Pons +7.43%
#10 Nesa Nesa +7.39%
Coin of the day
Verus Coin Verus Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rang in Aktien #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Aktienkurs
$0.1502
Zuletzt synchronisiert: 2024-11-04
Marktkapitalisierung
$6.43M
Veränderung (1 Tag)
-5.45%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Renalytix Plc (RNLX)

Kategorie

Healthcare
Operative Marge für Renalytix Plc (RNLX)
Operative Marge zum August 2026 TTM: -1,293.49%
Laut den neuesten Finanzberichten und dem Aktienkurs von Renalytix Plc beträgt die aktuelle operative Marge (TTM) -1,293.49%. Am Ende des Jahres 2023 lag die operative Marge bei -1,244.64%.
Historie der operativen Marge von Renalytix Plc von 2018 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -1,293.49% 0.00%
2024 -1,293.49% 3.92%
2023 -1,244.64% -35.57%
2022 -1,931.72% -11.68%
2021 -2,187.19% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
12.70% -100.01%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
74.17% -100.06%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
3.33% -100.00%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
-19.76% -99.98%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
0.00% -
US
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.